Acadian Asset Management LLC boosted its stake in Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) by 2.3% during the second quarter, Holdings Channel reports. The fund owned 41,978 shares of the specialty pharmaceutical company’s stock after buying an additional 941 shares during the period. Acadian Asset Management LLC’s holdings in Juniper Pharmaceuticals were worth $211,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the company. Goldman Sachs Group Inc. bought a new stake in Juniper Pharmaceuticals during the first quarter valued at $100,000. KCG Holdings Inc. bought a new stake in Juniper Pharmaceuticals during the first quarter valued at $112,000. TFS Capital LLC increased its stake in Juniper Pharmaceuticals by 87.0% in the first quarter. TFS Capital LLC now owns 31,619 shares of the specialty pharmaceutical company’s stock valued at $150,000 after buying an additional 14,707 shares in the last quarter. AWM Investment Company Inc. bought a new stake in Juniper Pharmaceuticals during the first quarter valued at $475,000. Finally, Algert Global LLC increased its stake in Juniper Pharmaceuticals by 28.9% in the first quarter. Algert Global LLC now owns 108,315 shares of the specialty pharmaceutical company’s stock valued at $514,000 after buying an additional 24,270 shares in the last quarter. 36.61% of the stock is owned by institutional investors and hedge funds.

Shares of Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) traded up 2.22% during trading on Wednesday, reaching $4.60. 1,749 shares of the company traded hands. Juniper Pharmaceuticals, Inc. has a 52 week low of $3.65 and a 52 week high of $7.12. The firm’s 50 day moving average price is $4.92 and its 200-day moving average price is $4.72. The company has a market capitalization of $49.88 million, a price-to-earnings ratio of 5.94 and a beta of 0.28.

Juniper Pharmaceuticals (NASDAQ:JNP) last released its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.10. The company had revenue of $13.96 million for the quarter, compared to analyst estimates of $11.84 million. Juniper Pharmaceuticals had a net margin of 13.94% and a return on equity of 21.49%. Equities analysts anticipate that Juniper Pharmaceuticals, Inc. will post ($0.51) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Acadian Asset Management LLC Has $211,000 Stake in Juniper Pharmaceuticals, Inc. (JNP)” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/acadian-asset-management-llc-has-211000-stake-in-juniper-pharmaceuticals-inc-jnp/1495789.html.

Several equities analysts recently issued reports on JNP shares. Roth Capital set a $12.00 price objective on shares of Juniper Pharmaceuticals and gave the company a “buy” rating in a report on Saturday, May 6th. ValuEngine lowered shares of Juniper Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. HC Wainwright reissued a “hold” rating on shares of Juniper Pharmaceuticals in a report on Monday, May 15th. Finally, BMO Capital Markets raised shares of Juniper Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $31.00 to $34.00 in a report on Friday, July 14th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $17.58.

About Juniper Pharmaceuticals

Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.

Want to see what other hedge funds are holding JNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Juniper Pharmaceuticals, Inc. (NASDAQ:JNP).

Institutional Ownership by Quarter for Juniper Pharmaceuticals (NASDAQ:JNP)

Receive News & Ratings for Juniper Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.